HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Pergolide (Permax)

A long-acting dopamine agonist which has been used to treat PARKINSON DISEASE and HYPERPROLACTINEMIA but withdrawn from some markets due to potential for HEART VALVE DISEASES.

Also Known As:

Permax; Athena Brand of Pergolide Mesylate; Celance; Draxis Brand of Pergolide Mesylate; Elanco Brand of Pergolide Mesylate; LY-127,809; LY-127809; Lilly Brand of Pergolide; Lilly Brand of Pergolide Mesylate; Parkotil; Pergolide Mesylate; Pharken; LY127,809; LY127809; Mesylate, Pergolide; Ergoline, 8-((methylthio)methyl)-6-propyl-, (8beta)-

Networked: 399 relevant articles (49 outcomes, 95 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 60
- Alkaloids: 1065
  - Ergot Alkaloids: 156
    - Ergolines: 88
      - Pergolide: 399
        6-methyl-8-((methylthio)methyl)ergoline (8beta)
        8-iodomethyl-6-propylergoline
        pergolide sulfone
        pergolide sulfoxide
        selenopergolide
- Heterocyclic Compounds with 4 or More Rings
  - Ergolines: 88
    - Pergolide: 399

Experts

1.	Rascol, Olivier: 6 articles (10/2011 - 05/2005)
2.	Bonuccelli, Ubaldo: 5 articles (12/2009 - 01/2002)
3.	Poewe, Werner: 4 articles (10/2011 - 08/2006)
4.	Cosyns, Bernard: 4 articles (06/2009 - 04/2004)
5.	Van Camp, Guy: 4 articles (06/2009 - 04/2004)
6.	Schwarz, Johannes: 4 articles (03/2006 - 12/2003)
7.	Hundemer, Hans-Peter: 4 articles (03/2006 - 01/2002)
8.	Antonini, Angelo: 3 articles (12/2011 - 01/2007)
9.	Seppi, Klaus: 3 articles (10/2011 - 08/2006)
10.	Sampaio, Cristina: 3 articles (10/2011 - 03/2006)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 11/01/1995 - "Pergolide is very effective for moderate to advanced Parkinson's disease." 04/01/1996 - "Our study demonstrated the good toleration and efficacy of pergolide treatment for Thai patients with Parkinson's disease. " 01/01/1991 - "A growing body of evidence suggests that pergolide does occupy and activate D1 receptors in vivo, although the relevance to therapeutic efficacy in Parkinson's disease needs further study." 12/01/1983 - "Pergolide is an effective and safe ongoing medication for Parkinson's disease." 03/01/1992 - "This finding was consistent with clinical reports of a subset of patients with Parkinson's disease in whom long-term efficacy of pergolide therapy is observed."
2.	Restless Legs Syndrome (Restless Legs) 09/15/1998 - "Thus, although pergolide at the dose of 0.25 mg at bedtime provided subjective improvement in symptoms of restless legs and quality of sleep, and objectively decreased leg movements during the first hour in bed, objectively sleep continued to be disrupted. " 04/27/2004 - "To evaluate the short- and long-term safety and efficacy of pergolide therapy for restless legs syndrome (RLS) in a double-blind, placebo-controlled, randomized trial (Pergolide European Australian RLS [PEARLS] study). " 04/27/2004 - "Efficacy of pergolide in treatment of restless legs syndrome: the PEARLS Study." 12/01/1998 - "To assess the efficacy of pergolide in the treatment of restless legs syndrome (RLS). " 05/22/2001 - "An open follow-up of a controlled study in patients with restless legs syndrome (RLS) shows that the beneficial effect of pergolide on RLS symptoms persists throughout at least 1 year. "
3.	Hyperprolactinemia 08/01/1983 - "The present study demonstrates the high potency, the good tolerance and the excellent efficacy of pergolide in the treatment of hyperprolactinaemia." 03/01/1990 - "It is proposed that, whenever TLE and hyperprolactinemia coexist, therapy with a DA agonist such as pergolide mesylate, resulting in normoprolactinemia, may be beneficial in TLE control." 09/26/1981 - "Preliminary evaluation of longer term treatment with pergolide indicates that this drug at a once-daily dose of 50-150 micrograms is a safe, well tolerated, and effective new treatment for hyperprolactinaemia." 08/29/1987 - "[Treatment of hyperprolactinemias by pergolide mesylate]." 01/01/1986 - "Control of hyperprolactinemia with pergolide."
4.	Dyskinesias (Dyskinesia) 09/01/2003 - "Dyskinesia decreased 25 % for relax and 17 % for task conditions under pergolide treatment. " 01/01/2000 - "Dyskinesia developed or deteriorated in 62% of pergolide-treated compared with 25% placebo-treated patients (p < 0. " 11/01/1998 - "The mean improvements in the UPDRS motor score in the off time and the activities of daily living (ADL) score were more than 50%; the mean off time decreased from 40 to 10%, and the mean dyskinesia and complication of treatment scores were reduced to one-third until pergolide was introduced at 12 months. " 09/01/2005 - "High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias." 09/01/1985 - "Pergolide was discontinued in 18 patients because of adverse effects, including an organic confusional syndrome (six patients), dyskinesias (four patients) and cardiovascular abnormalities (three patients). "
5.	Retroperitoneal Fibrosis 01/01/2009 - "Retroperitoneal fibrosis improved with pergolide cessation and corticosteroid treatment. " 01/01/2010 - "Retroperitoneal fibrosis secondary to pergolide therapy." 07/01/2000 - "Retroperitoneal fibrosis is a rare complication of pergolide therapy. " 07/01/2000 - "Pergolide-induced retroperitoneal fibrosis." 01/01/2009 - "Retroperitoneal fibrosis is best described as a chronic inflammatory process which may be idiopathic, but can rarely be brought about by medications, such as pergolide, used for treating Parkinson's disease. "

Related Drugs and Biologics

1.	Bromocriptine (Parlodel)
2.	Dopamine Agonists (Dopamine Agonist)
3.	Levodopa (L Dopa)
4.	pramipexol (pramipexole)
5.	cabergoline
6.	lergotrile
7.	levodopa drug combination carbidopa (Nakom)
8.	ropinirole (Requip)
9.	Dopamine (Intropin)
10.	Ergolines

Related Therapies and Procedures

1.	Activities of Daily Living (ADL)
2.	Injections
3.	Hypophysectomy
4.	Lasers (Laser)
5.	Vagotomy